Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 52, Issue 6

Issues

Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research

Ioannis Prassas
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
  • Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eleftherios P. Diamandis
  • Corresponding author
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
  • Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
  • Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-05 | DOI: https://doi.org/10.1515/cclm-2013-1078

With a global market of approximately $1.6 billion per year, antibodies (Abs) and Ab-based assays (e.g., ELISA, immunohistochemistry) represent foremost tools in translational studies [1]. The last decade has witnessed a boost in new biotech companies (mainly based in China, India and Brazil), which offer a wide variety of immunoassays for almost every analyte (even against analytes for which commercial demand should be theoretically small). In such a fast-paced, competitive environment, these new companies, instead of making their own reagents (Abs, antigens), often obtain them from external suppliers. The problem starts when these reagents are sold without having been rigorously validated. In fact, a few suppliers (mainly based in Asia) seem to provide the same reagents to different manufacturing companies, resulting in seemingly different ELISA kits (different vendors and catalogue numbers) which are based on the same Abs. Furthermore, in a globalized setting, where smaller biotech companies are continuously merging with existing ones, it is often extremely difficult to discern the roles of the different parties involved (suppliers, manufacturers and distributors). Under these circumstances, it should not be surprising that the quality standards of many of the newly developed immunoassays could be severely compromised.

The problem of market contamination with poor quality commercial Abs is not new [2, 3]. What is alarming is the extent to which this problem has escalated lately. Berglund et al. validated 5436 commercial antibodies from 51 different antibody providers (during the development of the Human Protein Atlas project) and found that half of the Abs could not pass established quality standards [4]. Expectedly, the problem of poor Ab development resulted in an increasing contamination of the market with unreliable ELISA assays [5, 6]. For instance, Gutiérrez et al. recently reported that an ELISA kit from USCN Life Sciences (Wuhan, China), which was designed to recognize human hemojuvelin, was not able to identify the analyte of interest but rather, an unknown protein, which was subsequently found to be the unrelated antigen, ferritin [7]. In our own recent report on a similar incident, we have shown that a kit purchased from the same company, designed to quantify CUB and Zona Pellucida-Like Domains Protein 1 (CUZD1), was unable to detect the analyte of interest but instead, the kit was quantifying the known ovarian cancer antigen, CA125 [8]. In the past, reports for unreliable ELISAs were mainly related to poor performance (e.g., precision) or possible cross-reactivities with other analyte(s). Based on our extensive experience on ELISA assay development and validation [9], we are aware that no ELISA kit is absolutely immune to cross-reactivity by unknown antigens. What is striking is that the two aforementioned examples, do not constitute cross-reactivity, but rather, recognition of an unrelated (by homology) antigen.

While we do not know how this could have happened during manufacturing, the consequences of such errors can be quite severe. We spent almost 2 years and approximately $500,000 to identify the antigen that the commercial assay for CUZD1 was measuring (CA125) [8]. Incidences like these also highlight additional possible harms, such as rejection of probably promising biomarkers, a situation that calls for a re-examination of such candidates by alternative technologies.

What does all this mean to translational researchers? Investigators around the world should be aware that certain suppliers are releasing with a fast pace ELISA kits of questionable quality. Such products can lead to unfounded conclusions, waste of many months of research and publications that subsequently need to be retracted. Based on the mounting growth of this problem, we encourage a more strict regulation of the antibody-based market even when the product is designated “for research use only”. In addition, there is an urgent need for the creation of independent bodies for standardized antibody validation (efforts towards this goal have already been initiated [10, 11]. Until these needs are met, the best immediate solution for researchers is to avoid purchasing kits from manufacturers that have been reported to produce kits of questionable quality. Table 1 summarizes some measures that should be taken to minimize similar problems in future translational studies.

Table 1

Recommendations to minimize future mishaps with Ab-based translational research.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

About the article

Corresponding author: Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University Health Network and University of Toronto, 600 University Avenue, C.P. 6128, Toronto, British Columbia, M5G 1X5, Canada, Phone: +1 416 5868443, Fax: +1 416 5868628, E-mail: ; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; and Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada


Published Online: 2014-02-05

Published in Print: 2014-06-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 52, Issue 6, Pages 765–766, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-1078.

Export Citation

©2014 by Walter de Gruyter Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Johann Mar Gudbergsson and Meg Duroux
Journal of Cellular Biochemistry, 2019
[2]
Monya Baker
Nature, 2015, Volume 521, Number 7552, Page 274
[3]
David Cyranoski
Nature, 2017, Volume 545, Number 7653, Page 148
[4]
Peter J Selby, Rosamonde E Banks, Walter Gregory, Jenny Hewison, William Rosenberg, Douglas G Altman, Jonathan J Deeks, Christopher McCabe, Julie Parkes, Catharine Sturgeon, Douglas Thompson, Maureen Twiddy, Janine Bestall, Joan Bedlington, Tilly Hale, Jacqueline Dinnes, Marc Jones, Andrew Lewington, Michael P Messenger, Vicky Napp, Alice Sitch, Sudeep Tanwar, Naveen S Vasudev, Paul Baxter, Sue Bell, David A Cairns, Nicola Calder, Neil Corrigan, Francesco Del Galdo, Peter Heudtlass, Nick Hornigold, Claire Hulme, Michelle Hutchinson, Carys Lippiatt, Tobias Livingstone, Roberta Longo, Matthew Potton, Stephanie Roberts, Sheryl Sim, Sebastian Trainor, Matthew Welberry Smith, James Neuberger, Douglas Thorburn, Paul Richardson, John Christie, Neil Sheerin, William McKane, Paul Gibbs, Anusha Edwards, Naeem Soomro, Adebanji Adeyoju, Grant D Stewart, and David Hrouda
Programme Grants for Applied Research, 2018, Volume 6, Number 3, Page 1
[5]
Simon L. Goodman
Journal of Cell Science, 2018, Volume 131, Number 10, Page jcs216416
[6]
Andrew R.M. Bradbury, Nathan D. Trinklein, Holger Thie, Ian C. Wilkinson, Atul K. Tandon, Stephen Anderson, Catherine L. Bladen, Brittany Jones, Shelley Force Aldred, Marco Bestagno, Oscar Burrone, Jennifer Maynard, Fortunato Ferrara, James S. Trimmer, Janina Görnemann, Jacob Glanville, Philipp Wolf, Andre Frenzel, Julin Wong, Xin Yu Koh, Hui-Yan Eng, David Lane, Marie-Paule Lefranc, Mike Clark, and Stefan Dübel
mAbs, 2018, Page 1
[7]
Manish Mishra, Shuchita Tiwari, and Aldrin V. Gomes
Expert Review of Proteomics, 2017, Page 1
[8]
Yu-Tsen Lin, Cheng-Kai Wang, Shang-Chih Yang, Shu-Ching Hsu, Hsuan Lin, Fang-Pei Chang, Tzu-Chien Kuo, Chia-Ning Shen, Po-Ming Chiang, Michael Hsiao, Frank Leigh Lu, and Jean Lu
Scientific Reports, 2017, Volume 7, Number 1
[9]
Poulomi Acharya, Anna Quinlan, and Veronique Neumeister
F1000Research, 2017, Volume 6, Page 851
[10]
Kelly Barford, Chan Choo Yap, Noelle D. Dwyer, and Bettina Winckler
Journal of Comparative Neurology, 2017, Volume 525, Number 8, Page 1861
[11]
Callum J. C. Parr, Shota Katayama, Kenji Miki, Yi Kuang, Yoshinori Yoshida, Asuka Morizane, Jun Takahashi, Shinya Yamanaka, and Hirohide Saito
Scientific Reports, 2016, Volume 6, Number 1
[12]
Pranali Patel, Uros Kuzmanov, and Seema Mital
BMC Biochemistry, 2016, Volume 17, Number 1
[13]
Marilyne Dupin, Tanguy Fortin, Audrey Larue-Triolet, Isabelle Surault, Corinne Beaulieu, Aurélie Gouel-Chéron, Bernard Allaouchiche, Karim Asehnoune, Antoine Roquilly, Fabienne Venet, Guillaume Monneret, Xavier Lacoux, Carolyn A. Roitsch, Alexandre Pachot, Jean-Philippe Charrier, and Sylvie Pons
Journal of Proteome Research, 2016, Volume 15, Number 8, Page 2366
[14]
Eduardo Martínez-Morillo, Charmaine Childs, Belén Prieto García, Francisco V. Álvarez Menéndez, Alexander D. Romaschin, Gianfranco Cervellin, Giuseppe Lippi, and Eleftherios P. Diamandis
Clinical Chemistry and Laboratory Medicine (CCLM), 2015, Volume 53, Number 10

Comments (0)

Please log in or register to comment.
Log in